Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21078676 | 0.83 | SLC2A1 (0.49) | SLC2A1ADORA2AADORA2BADORA1HSP90B1 | |
| SCHEMBL12946398 | 0.80 | ADORA2A (0.40) | MKNK2PRMT5WDR77ADORA2AADORA2B | |
| SCHEMBL13243608 | 0.75 | KMT2A (0.35) | MKNK2PRMT5WDR77 | |
| SCHEMBL25810956 | 0.74 | SLC2A1 (0.46) | BRD4SLC2A1 | |
| SCHEMBL24239193 | 0.73 | ADA (0.50) | — | |
| SCHEMBL19711212 | 0.71 | ADORA2A (0.39) | MKNK2PRMT5WDR77ADORA2AADORA1 | |
| SCHEMBL26153000 | 0.71 | TLR7 (0.38) | SLC2A1MKNK2PRMT5WDR77ADORA2A | |
| SCHEMBL21943146 | 0.70 | ADORA2A (0.59) | SLC2A1PRMT5WDR77ADORA2AADORA2B | |
| SCHEMBL20733588 | 0.70 | ADORA2A (0.44) | ADORA2AADORA2BADORA1 | |
| SCHEMBL13243610 | 0.69 | MKNK2 (0.36) | MKNK2PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | BRD4 2445/4885SLC2A1 2104/4885MKNK2 1527/4885 |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | BRD4 2445/4885SLC2A1 2104/4885MKNK2 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.